Regulus Therapeutics Competitors and Similar CompaniesClear all
Regulus Therapeutics's competitors and similar companies include Moderna and Alnylam.
 Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. |  Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 2007 | Founding Date 2010 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations San Diego, US HQ | ||
Employees | Employees 2462% decrease | Employees 5,8004% increase | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 105.4 m | Valuation ($) 21.2 b | Valuation ($) 36.5 b |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.9b (FY, 2025) | Revenue (est.) $3.7b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $868m (FY, 2025) | Cost of goods $677.2m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $1.1b (FY, 2025) | Gross profit $3b (FY, 2025) |
Net income | Net income ($46.4m) (FY, 2024) | Net income ($2.8b) (FY, 2025) | Net income $313.7m (FY, 2025) |
Operating ⚠ | |||
Patents Issued | Patents Issued 300 (FY, 2016) | Patents Issued 270 (FY, 2020) | Patents Issued N/A |
Funding | |||
Total funding raised | Total funding raised $ 10m | Total funding raised $ 1.8b | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Moderna
HQ
Cambridge, US
Employees
5,800↑ 4% increase
Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company